Aytu BioPharma initiated with a Buy at Ascendiant

Ascendiant initiated coverage of Aytu BioPharma (AYTU) with a Buy rating and $12 price target Aytu recently announced an agreement with Fabre-Kramer Pharmaceuticals to commercialize Exxua extended-release tablets in the U.S. for the treatment of Major Depressive Disorder in adults, notes the analyst, who sees large market opportunities for its new drug. Exxua was approved by the FDA in September 2023 and has not yet been sold commercially, notes the analyst, who also points out that the drug has been shown to effectively relieve depressive symptoms and that its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain.